Keyword: Richard Blumenthal
It didn't take long for Congress to push back at Allergan's first-of-a-kind patent deal with the Saint Regis Mohawk Tribe.
Mylan has finished a settlement with the Department of Justice for $465 million relating to EpiPen’s misclassification on Medicaid.
After taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
A host of Big Pharmas have promised to limit their price hikes, but Pfizer isn't one of them—and that has some investors riled.
Mylan has agreed to meet with Sen. Chuck Grassley, who is investigating a Medicaid drug misclassification that cost taxpayers more than $1.2 billion.
Mylan agreed to pay $465M to settle a federal probe into underpaid Medicaid rebates, but that's less than half the cost to taxpayers, HHS says.
Facing fire over EpiPen pricing, Mylan worked quickly this month to settle federal allegations that it overcharged Medicaid. Now, one senator says that $465 million deal wasn’t enough. He wants more cash--and a deeper investigation.
Mylan has been fighting for more than a year to block Teva’s generic EpiPen. But all along EpiPen itself has been classified as a generic drug for Medicaid patients--and now, U.S. senators are calling on the Justice Department to find out why.